Laurus Labs (LAURUSLABS) Share Price Falls 2.67% to Rs 1,871.60
- September 16, 2026
- Posted by: Harsh Piplani
- Category: News
Laurus Labs Share Price fell 2.67% to Rs 1,871.60 on 16 September 2026, taking the company’s market capitalisation to Rs 1,06,460.42 crore. The decline came after the stock opened at Rs 1,925.95 and moved between Rs 1,863.75 and Rs 1,939.70 during the session. The supplied data confirms the price event, but it does not establish a company-specific catalyst. In that setting, Laurus Labs Share Price Today becomes a question of what the market data itself shows: a lower close than the previous close of Rs 1,923, a negative day change of Rs 51.40, and a healthcare company valued at a large-cap scale by market capitalisation context. This Laurus Labs Stock News update therefore focuses on verified price action, valuation, sector context and peers.
Laurus Labs (LAURUSLABS) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,871.6 |
| Previous Close | Rs 1,923 |
| Today's Move | -Rs 51.40 (-2.67%) |
| Open | Rs 1,925.95 |
| High | Rs 1,939.7 |
| Low | Rs 1,863.75 |
| Turnover | Rs 16.44 crore |
| Market Capitalisation | Rs 1,06,460.42 crore |
| Market Cap Category | Large Cap |
Laurus Labs Share Price Today closed at Rs 1,871.60 compared with the previous close of Rs 1,923, marking a day decline of Rs 51.40 or 2.67%. The stock opened at Rs 1,925.95, touched an intraday high of Rs 1,939.70 and a low of Rs 1,863.75. Turnover stood at Rs 16.44 crore. The move left Laurus Labs in the Large Cap category, using the supplied market-cap classification, with a market capitalisation of Rs 1,06,460.42 crore. On a simple price-action basis, the share price spent the session below its opening price and below the previous close, which is why Laurus Labs Share Price Fall is the key event in today’s market update. For readers tracking Laurus Labs Stock Falling Today, the verified figures show a softer close within a fairly narrow intraday band, and that sets up the next layer of analysis around valuation and sector positioning.
Laurus Labs (LAURUSLABS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,06,460.42 crore |
| P/E Ratio | 95.03x |
| P/B Ratio | 18.43x |
| ROE | 18.31% |
| ROCE | 18.2% |
| EPS | Rs 20.24 |
| Book Value Per Share | Rs 104.37 |
| Dividend Yield | 0.1% |
Laurus Labs has a market capitalisation of Rs 1,06,460.42 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 95.03x, P/B at 18.43x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 18.31% and ROCE of 18.2%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 20.24, book value per share of Rs 104.37, dividend yield of 0.1%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.74x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 95.03x |
| Benchmark Median P/E | 31.74x |
| Benchmark Average P/E | 47.98x |
| Benchmark P/E Range | 3.29x to 683.37x |
| Company P/B Ratio | 18.43x |
| Benchmark Median P/B | 3.02x |
| Benchmark Average P/B | 4.44x |
| Company ROE | 18.31% |
| Benchmark Median ROE | 11.78% |
| Benchmark Average ROE | 11.19% |
| Company ROCE | 18.2% |
| Benchmark Median ROCE | 13.65% |
| Benchmark Average ROCE | 13.65% |
| Company Market Capitalisation | Rs 1,06,460.42 crore |
| Benchmark Median Market Cap | Rs 750.5 crore |
| Benchmark Average Market Cap | Rs 14,144.11 crore |
Laurus Labs operates in Healthcare, within the Pharmaceuticals & Drugs industry, and the supplied benchmark covers the same industry with 200 companies. Against that universe, Laurus Labs Share Price sits at a P/E of 95.03 versus a benchmark median of 31.74 and average of 47.98. The company’s P/B of 18.43 also stands above the benchmark median of 3.02 and average of 4.44. On returns, Laurus Labs’ ROE of 18.31% is above the benchmark median of 11.78%, while ROCE of 18.2% is above the benchmark median and average of 13.65%. The sector benchmark market capitalisation median is Rs 750.5 crore and the average is Rs 14,144.11 crore, while Laurus Labs’ market capitalisation is Rs 1,06,460.42 crore, placing it well above the benchmark average. This sector view does not explain the day’s fall, but it does show how Laurus Labs Share Price compares on valuation and operating returns within healthcare.
The same-industry benchmark also helps frame Laurus Labs Stock News in a wider market context. Sun Pharmaceutical Industries trades at a P/E of 36.4, P/B of 5.09, ROE of 14.85% and ROCE of 19.11%, with a market capitalisation of Rs 4,41,957.5 crore. Divi’s Laboratories shows a P/E of 83.41, P/B of 13.81, ROE of 16.19% and ROCE of 21.51%, with market capitalisation of Rs 2,47,576 crore. Torrent Pharmaceuticals has a P/E of 84.58, P/B of 20.55, ROE of 26.76% and ROCE of 19.27%, with market capitalisation of Rs 1,89,233.01 crore. Zydus Lifesciences trades at a P/E of 24.29, P/B of 4.07, ROE of 19.69% and ROCE of 21.39%, with market capitalisation of Rs 1,11,670.55 crore. That mix shows Laurus Labs Share Price at a richer valuation than several listed healthcare names while operating returns remain competitive.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,957.5 | 36.4 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,47,576 | 83.41 | 13.81 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,233.01 | 84.58 | 20.55 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,670.55 | 24.29 | 4.07 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,10,272.68 | 32.62 | 3.13 | 11.83 | 16 |
The peer set places Laurus Labs among several established pharmaceutical companies with varied valuation and return profiles. Laurus Labs’ P/E of 95.03 is higher than Sun Pharmaceutical Industries at 36.4, Zydus Lifesciences at 24.29 and Cipla at 32.62, while it is closer to Divi’s Laboratories at 83.41 and Torrent Pharmaceuticals at 84.58. On P/B, Laurus Labs at 18.43 is below Torrent Pharmaceuticals at 20.55, but above Sun Pharmaceutical Industries at 5.09, Divi’s Laboratories at 13.81, Zydus Lifesciences at 4.07 and Cipla at 3.13. ROE at 18.31% is stronger than Sun Pharma, Divi’s and Cipla, but below Torrent and Zydus. ROCE at 18.2% is ahead of Sun Pharma and Cipla, close to Torrent, and below Divi’s, Zydus and Lupin. In market-cap terms, Laurus Labs Share Price sits below the largest peers but above the smaller ones in the supplied comparison set.
Why Investors Are Watching Laurus Labs
- Laurus Labs Share Price fell 2.67% to Rs 1,871.60, below the previous close of Rs 1,923.
- The stock moved between Rs 1,863.75 and Rs 1,939.70 after opening at Rs 1,925.95.
- Turnover for the session was Rs 16.44 crore.
- Market capitalisation stood at Rs 1,06,460.42 crore, and the stock is in the Large Cap category.
- Valuation metrics show a P/E of 95.03, P/B of 18.43, ROE of 18.31% and ROCE of 18.2%.
About Laurus Labs
Laurus Labs is classified in Healthcare and the Pharmaceuticals & Drugs industry. The supplied dataset does not add a longer business description, so the company profile here remains to that verified classification. For Laurus Labs Share Price readers, that means the most reliable context in this article comes from the day’s price action, the valuation ratios, and the same-industry comparison set. Laurus Labs Stock News should therefore be read with the factual lens of a healthcare company operating in a sector where PE, PB, ROE and ROCE vary widely across listed peers.
Track Laurus Labs Share Price on Univest
Use Laurus Labs (LAURUSLABS) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Track Laurus Labs Share Price on Univest to follow live price updates, key valuation ratios, shareholding pattern, 52-week levels and market insights in one place. Univest also brings together stock performance context, financial ratios and company-level updates for easier monitoring.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Laurus Labs Share Price fall today?
Ans. The data confirms a 2.67% decline in Laurus Labs Share Price to Rs 1,871.60, but it does not establish a company-specific catalyst. The session also saw an intraday range of Rs 1,863.75 to Rs 1,939.70.
What was Laurus Labs Share Price Today’s closing level?
Ans. Laurus Labs Share Price Today closed at Rs 1,871.60, below the previous close of Rs 1,923. The day change was Rs 51.40 lower, which is a 2.67% fall in the session.
What is Laurus Labs market capitalisation?
Ans. Laurus Labs has a market capitalisation of Rs 1,06,460.42 crore and is classified as a Large Cap stock in the supplied data. That size context is factual and does not explain the price move.
How does Laurus Labs compare on valuation?
Ans. Laurus Labs trades at a P/E of 95.03 and a P/B of 18.43, both above the same-industry benchmark medians. Its ROE of 18.31% and ROCE of 18.2% are also above the benchmark median levels.
What do Laurus Labs EPS, book value and dividend yield show?
Ans. Laurus Labs reports EPS of Rs 20.24, book value of Rs 104.37 and dividend yield of 0.1%. EPS reflects earnings per share, book value shows accounting net worth per share, and dividend yield reflects historical payout.
How does Laurus Labs compare with peers?
Ans. Laurus Labs has a higher P/E than Sun Pharma, Zydus Lifesciences and Cipla, while its ROE and ROCE sit in the mid-to-upper range versus the listed healthcare peers in the supplied comparison set.
